99艾滋病论坛

 找回密码
 注_册

QQ登录

只需一步,快速开始

扫一扫,访问微社区

查看: 4930|回复: 0

耐多重药物结核病治疗获得新突破

[复制链接]
发表于 2014-7-25 08:10:18 | 显示全部楼层 |阅读模式


  在第20届世界艾滋病大会第一天,一项关于肺结核治疗的重大突破向世人宣告。实验用一个新的三种药物的鸡尾酒疗法去治疗一个感染结核菌株的病人,这个病人用传统的抗生素很难治愈。结果这个感染了多重耐药结核的病人不仅获得了很好的治疗,而且治疗时间也大大缩短。


    目前,全世界有650000人患有耐多药结核病(MDR)。全球每年新增900万感染病人,耐多药结核病的患者的数量还会继续增长。大多数病人由于经济、地理和物理约束的原因,无法获得适当治疗。新的解决方案用时短,成本较低,具有更好的耐受性,在口服剂量和抗逆转录病毒疗法中治疗结核病有很好的兼容性。

    试验报告测试了这种新药,PaMZ,不同于标准药物异烟肼、利福平、吡嗪酰胺和乙胺丁醇——测试在207名南非志愿者中进行。这群人中有五分之一的人群也感染了艾滋病病毒。结果表明,经过八个星期都的测试后,71%的使用PaMZ疗法的患者清除了体内结核杆菌痰,而采用标准HRZE疗法的对照组患者,只有38%获得这一疗效。。

    认可这个新的治疗方案时市场上这可能意味着结核病治疗会变得更便宜、更安全、更有效。意义更大或改进获得结核病治疗和转化为成本节约超过90%的在一些国家,如耐多药治疗是复杂和劳动密集型。

    一旦这个新的治疗方案能够在市场上推行,就意味着结核病治疗将会变得更便宜,更安全,更有效。更重要的是,在一些国家进行结核病治疗将会节约超过90%的成本,隐者这些国家的耐多药治疗很复杂,需要投入大量人力。

原问题目《Breakthrough in multi-drug resistant TB treatmen》

英文原文:
  At the first day of the 20th International AIDS Conference a major breakthrough in treatment of tuberculosis (TB) has been announced. Experiments with a new cocktail of three drugs to treat patients infected with TB strains that are hard to cure with conventional antibiotics, can not only improve the treatment of TB and its multi-drug resistant strains, but also shorten the treatment period.

  Currently, 650,000 people around the world suffer from multi-drug resistant (MDR) TB. With a global increase of 9 million new infectious each year, the number of people suffering of MDR TB is only expected to grow. As most patients are unable to access adequate treatment due to economic, geographic and physical constraints, new regimens that are shorter, less costly, better tolerated, in oral doses and compatible with anti-retroviral therapy are urgently needed to treat TB.

  The trial reported entailed testing the new drug regimen, PaMZ, against standard drugs - isoniazid, rifampicin, pyrazinamide and ethambutol - among 207 volunteers in South Africa. One fifth of the cohort were co-infected with HIV. Results showed that 71 percent of the participants on PaMZ were cleared of TB bacteria in their sputum at the end of the eight week treatment scheme, versus 38 percent of people in the control group who were taking the standard HRZE therapy.

  When this new treatment regime is accredited on the market this could mean that TB treatment can become, cheaper, safer and more effective. Meaning greater or improved access to TB treatment and translating into cost savings of more than 90 percent in some countries, as MDR therapy is complex and labour-intensive.

本帖子中包含更多资源

您需要 登录 才可以下载或查看,没有帐号?注_册

x
您需要登录后才可以回帖 登录 | 注_册

本版积分规则

  • 客服QQ:800962
  • 红丝带之家
  • 咨询:21885399
  • 艾滋病在线咨询服务
  • 添加微信:hivaizi

  • 扫一扫,加微信在线咨询

QQ|手机版|99艾滋病论坛  点击这里给我发消息

GMT+8, 2018-11-20 02:20 , Processed in 0.310066 second(s), 36 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表